This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
El Resumen Visual
El Ferzartamab muestra resultados prometedores en el tratamiento del rechazo mediado por anticuerpos en trasplantados renales. En este ensayo clínico fase 2 aleatorizado, se evaluó el perfil de seguridad y los resultados secundarios a las 24 semanas.
¿Podría este anticuerpo anti-CD38 ser la nueva opción terapéutica revolucionaria para prevenir la pérdida del injerto mediada por anticuerpos? Observa el resumen visual realizado por el pasante del NSMC, Dr. Shahin Mohammed.
